MY210469A - Pcsk9 inhibitors and methods of use thereof - Google Patents

Pcsk9 inhibitors and methods of use thereof

Info

Publication number
MY210469A
MY210469A MYPI2021003994A MYPI2021003994A MY210469A MY 210469 A MY210469 A MY 210469A MY PI2021003994 A MYPI2021003994 A MY PI2021003994A MY PI2021003994 A MYPI2021003994 A MY PI2021003994A MY 210469 A MY210469 A MY 210469A
Authority
MY
Malaysia
Prior art keywords
methods
pcsk9 inhibitors
pcsk9
inhibitors
bind
Prior art date
Application number
MYPI2021003994A
Inventor
Doug Daniels
Virendar Kaushik
Brian K Hubbard
Michael H Serrano-Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY210469A publication Critical patent/MY210469A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
MYPI2021003994A 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof MY210469A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794239P 2019-01-18 2019-01-18
PCT/US2020/013882 WO2020150474A1 (en) 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MY210469A true MY210469A (en) 2025-09-24

Family

ID=71608564

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021003994A MY210469A (en) 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof

Country Status (16)

Country Link
US (2) US11603523B2 (en)
EP (2) EP3911640B1 (en)
JP (2) JP2022518016A (en)
KR (2) KR20210116549A (en)
CN (1) CN113412258A (en)
AU (3) AU2020209216A1 (en)
BR (1) BR112021013924A2 (en)
CA (1) CA3125767A1 (en)
EA (1) EA202191890A1 (en)
IL (1) IL284661A (en)
MA (1) MA54758A (en)
MX (2) MX2021008661A (en)
MY (1) MY210469A (en)
SG (1) SG11202107615TA (en)
TW (1) TWI921300B (en)
WO (1) WO2020150474A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013924A2 (en) 2019-01-18 2021-09-21 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USING THEM
WO2020150473A2 (en) * 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN113248501B (en) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 CLY series compounds, preparation method thereof and application thereof in preparing medicines
CN113735846A (en) * 2021-10-11 2021-12-03 河北师范大学 Benzothiazole derivative and medical application thereof
WO2023084449A1 (en) * 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
TW202329937A (en) 2021-12-03 2023-08-01 美商英塞特公司 Bicyclic amine cdk12 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20240217951A1 (en) * 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121913991A (en) * 2022-10-14 2026-04-24 上海翰森生物医药科技有限公司 Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof
CN119264042A (en) * 2023-07-04 2025-01-07 上海翰森生物医药科技有限公司 Cyclopentane derivative inhibitor, preparation method and application thereof
CN121443616A (en) 2023-07-27 2026-01-30 上海拓界生物医药科技有限公司 Diaminocyclopentyl-substituted heteroaryl derivatives, their uses and preparation methods
TW202547505A (en) 2024-02-05 2025-12-16 瑞典商阿斯特捷利康公司 Pharmaceutical compositions comprising azd0780
TW202545529A (en) 2024-02-05 2025-12-01 瑞典商阿斯特捷利康公司 Combination therapy
WO2025183455A1 (en) * 2024-02-29 2025-09-04 재단법인 대구경북첨단의료산업진흥재단 Benzoxazole derivatives as pcsk9 inhibitor
TW202539678A (en) * 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Pcsk9 inhibitors and methods of use thereof
WO2025214500A1 (en) * 2024-04-12 2025-10-16 上海翰森生物医药科技有限公司 Free base crystal form of nitrogen-containing heterocyclic derivative, acid salt and crystal form thereof, preparation method therefor, and use thereof
TW202612699A (en) 2024-05-16 2026-04-01 瑞典商阿斯特捷利康公司 Combination therapy
WO2026021380A1 (en) * 2024-07-22 2026-01-29 深圳信立泰药业股份有限公司 Pcsk9 and hmg-coa dual-target compound and use thereof
WO2026026878A1 (en) * 2024-07-30 2026-02-05 成都施贝康生物医药科技有限公司 Heterocyclic derivative inhibitor, and preparation thereof and use thereof
WO2026086805A1 (en) * 2024-10-23 2026-04-30 深圳信立泰药业股份有限公司 Pcsk9 and hmg-coa bicyclic compound, and preparation and use thereof
WO2026092600A1 (en) * 2024-10-31 2026-05-07 石药集团中奇制药技术(石家庄)有限公司 Nitrogen-containing heterocyclic compound and use thereof
WO2026093543A1 (en) 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and pcsk9 inhibitor combination therapy
WO2026092659A1 (en) * 2024-11-01 2026-05-07 盛睿泽华医药科技(苏州)有限公司 Polycyclic compound, preparation method therefor, and use thereof
WO2026131688A2 (en) * 2024-12-16 2026-06-25 Astrazeneca Ab Crystalline forms and methods of synthesis
WO2026145737A1 (en) * 2025-01-03 2026-07-09 江苏豪森药业集团有限公司 Salt of class of nitrogen-containing heterocyclic derivatives and crystal form thereof, preparation method therefor, and use thereof
WO2026158426A1 (en) * 2025-01-23 2026-07-30 江苏恒瑞医药股份有限公司 Crystal forms of diaminocyclopentyl-substituted heteroaryl derivative and preparation method therefor
WO2026158425A1 (en) * 2025-01-23 2026-07-30 江苏恒瑞医药股份有限公司 Pharmaceutically acceptable salt of diaminocyclopentyl-substituted heteroaryl derivative, crystalline form thereof, and use thereof
WO2026158633A1 (en) * 2025-01-27 2026-07-30 乐普(北京)医疗器械股份有限公司 Nitrogen-containing heterocyclic compound small-molecule inhibitor and use thereof

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CA2192203A1 (en) 1994-06-17 1995-12-28 Werner Hofheinz N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
SE9603285D0 (en) 1996-09-10 1996-09-10 Astra Ab New compounds
US5874438A (en) 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
DE69818675T2 (en) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth GALACTOMANAN POLYMERS AND BORATE CONTAINING EYE MEDICINAL PRODUCTS
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20040138284A1 (en) 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
GB0014022D0 (en) 2000-06-08 2000-08-02 Novartis Ag Organic compounds
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
JP2005519895A (en) 2002-01-18 2005-07-07 ファルマシア・コーポレーション Substituted pyridazinones as P38 inhibitors
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
WO2004017920A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CA2510793A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
WO2004094471A2 (en) 2003-04-22 2004-11-04 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXJL06000069A (en) * 2004-06-09 2007-04-10 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases.
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
JP2008514546A (en) 2004-09-30 2008-05-08 大正製薬株式会社 Pyridine derivatives and therapies associated with their use
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
CA2598043A1 (en) 2005-02-25 2006-08-31 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing hcv infection
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
EA015890B1 (en) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Pyrimidine compounds
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
JP2007291087A (en) 2006-03-29 2007-11-08 Taisho Pharmaceut Co Ltd Pyridine derivatives and therapies associated with their use
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
WO2008072963A1 (en) 2006-12-13 2008-06-19 Givaudan Nederland Services B.V. Flavour modulating derivative of a carboxylic acid and a purine, pyrimidine, nucleoside or nucleotide
CN102232088A (en) * 2007-10-26 2011-11-02 先灵公司 Anti-PCSK9 and methods for treating lipid and cholesterol disorders
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN107233337A (en) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 Pharmaceutical composition containing EPA and cardiovascular agents and use its method
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
RU2012104214A (en) 2009-08-05 2013-09-10 Верситек Лимитед ANTIVIRAL COMPOUNDS AND METHODS FOR PRODUCING AND USING THEM
US8952037B2 (en) 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
KR20130111512A (en) 2010-06-04 2013-10-10 코와 가부시키가이샤 Optically active dibenzylamine derivatives and preparation methods thereof
CA2802952A1 (en) 2010-06-24 2011-12-29 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
AU2011270719B2 (en) 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012101062A1 (en) 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
AU2012258618B2 (en) 2011-05-26 2017-05-25 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
JP5741850B2 (en) 2011-09-13 2015-07-01 コニカミノルタ株式会社 Optical film, polarizing plate including the same, and liquid crystal display device
JP6295205B2 (en) 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. How to reduce the risk of cardiovascular disease
TW201348231A (en) 2012-02-29 2013-12-01 Amgen Inc Heterobicyclic compounds
US9567316B2 (en) 2012-03-07 2017-02-14 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
WO2013137371A1 (en) 2012-03-15 2013-09-19 興和株式会社 Novel pyrimidine compound and medicine comprising same
US9658211B2 (en) 2012-04-18 2017-05-23 Hemoshear, Llc In vitro model for pathological or physiologic conditions
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
AR092924A1 (en) 2012-10-09 2015-05-06 Sanofi Sa PIRROLIDINONE DERIVATIVES AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US10059671B2 (en) 2013-02-04 2018-08-28 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
RS62649B1 (en) 2013-03-12 2021-12-31 Vertex Pharma Dna-pk inhibitors
CN105143203A (en) 2013-04-17 2015-12-09 辉瑞大药厂 N-piperidin-3-ylbenzamide derivatives for the treatment of cardiovascular diseases
TWI682780B (en) 2013-05-30 2020-01-21 美商再生元醫藥公司 Use of a pharmaceutical composition for the manufacture of a medicament for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
TW201534324A (en) 2013-06-07 2015-09-16 Sanofi Sa Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
AR092240A1 (en) 2013-08-26 2015-04-08 Sunshine Lake Pharma Co Ltd NITROGEN HETEROCICLIC DERIVATIVES AND ITS APPLICATION IN PHARMACOS
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX373298B (en) 2013-10-11 2020-05-20 Sanofi Biotechnology USE OF A PCSK9 INHIBITOR TO TREAT HYPERLIPIDEMIA.
CN104558685B (en) 2013-10-24 2017-09-29 中国石油化工股份有限公司 A kind of phosphorus nitrogen expansion type combustion inhibitor and its synthetic method
JP2017019724A (en) 2013-10-25 2017-01-26 第一三共株式会社 Substituted pyridine compounds and other pharmaceutical combinations
WO2015086723A2 (en) 2013-12-11 2015-06-18 Glycotope Gmbh Glycosylated glycophorin peptides
TW201609798A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
CU24395B1 (en) 2014-03-17 2019-04-04 Pfizer DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS
AR099937A1 (en) 2014-04-04 2016-08-31 Sanofi Sa ISOINDOLINONE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
RU2016143092A (en) 2014-04-04 2018-05-08 Санофи SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR TREATING DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
AR099936A1 (en) 2014-04-04 2016-08-31 Sanofi Sa CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
EP3148537B1 (en) 2014-05-30 2018-09-26 Université Paris Descartes Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI744723B (en) 2014-06-20 2021-11-01 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
AU2015289617B2 (en) 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
ES2907461T3 (en) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and methods of use thereof
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
AR103954A1 (en) 2015-03-18 2017-06-14 Zealand Pharma As AMILINE ANALOGS
EP3271405A1 (en) 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
PL3283507T3 (en) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylated glucagon analogue
MX2018005096A (en) 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Gemcabene combinations for the treatment of cardiovascular disease.
TW201731867A (en) 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variant
EP4085934A1 (en) 2015-12-11 2022-11-09 The Trustees of The University of Pennsylvania Gene therapy for treating familial hypercholesterolemia
BR112018014794A2 (en) 2016-01-20 2018-12-11 Janssen Sciences Ireland Uc aryl substituted pyrimidines for use in influenza virus infection
SG10201912756XA (en) 2016-02-26 2020-02-27 Gemphire Therapeutics Inc Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CA3020087A1 (en) 2016-04-14 2017-10-19 Michael LUCEY Combinational compositions and methods of use thereof
TW201808888A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10960020B2 (en) 2016-09-15 2021-03-30 The Brigham And Women's Hospital, Inc. Modulation of PCSK9 and LDLR through DRP1 inhibition
HRP20240930T1 (en) 2016-10-18 2024-10-11 Novartis Ag Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
KR20240044543A (en) 2016-11-10 2024-04-04 시에스엘 리미티드 Reconstituted high density lipoprotein treatment of myocardial infarction
JOP20190112A1 (en) 2016-11-14 2019-05-14 Amgen Inc Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
MA48602A (en) 2016-12-13 2020-03-18 Bristol Myers Squibb Co HETEROARYL COMPOUNDS SUBSTITUTED BY AN ALKYL PHOSPHINE OXIDE AMIDE AS MODULATORS OF IL-12, IL-23 AND / OR IFN ALPHA RESPONSES
EP3579782B1 (en) 2017-02-08 2024-05-01 Brooke Schumm Intra-operative radiation therapy capsule with cylindrical shell radiation containment shutter system
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AR110988A1 (en) 2017-02-21 2019-05-22 Sanofi Sa AZETIDINE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
EP3609882B1 (en) 2017-03-17 2022-07-13 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
CN110691779B (en) 2017-03-24 2023-10-10 库拉肿瘤学公司 Approaches to Treating Hematologic Malignancies and Ewing's Sarcoma
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN110831593A (en) 2017-06-14 2020-02-21 特维娜有限公司 Compounds for modulating S1P1 activity and methods of using the same
JP6928986B2 (en) 2017-06-26 2021-09-01 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. Indazole compounds, compositions and uses thereof for inhibiting kinase activity
CN109384712B (en) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 NK1 receptor targeting antagonist and application thereof in treatment of nausea and vomiting caused by chemotherapy
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11400082B2 (en) 2017-10-30 2022-08-02 Montréal Heart Institute Methods of treating elevated plasma cholesterol
CN111315772A (en) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 anti-APOC 3 antibodies and methods of use thereof
UY37957A (en) 2017-11-02 2019-05-31 Abbvie Inc INTEGRATED STRESS ROAD MODULATORS
MY202167A (en) 2017-11-21 2024-04-12 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
WO2019111225A1 (en) 2017-12-08 2019-06-13 Avaliv Therapeutics Compounds and methods for the treatment of non‑alcoholic steatohepatitis
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
BR112020014140A2 (en) * 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated dna-pk inhibitors
US11513131B2 (en) 2018-01-22 2022-11-29 Global Genomics Group, LLC Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
US11911445B2 (en) 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
US20210324067A9 (en) 2018-03-09 2021-10-21 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
JP7485609B2 (en) 2018-03-22 2024-05-16 ブリストル-マイヤーズ スクイブ カンパニー Pyridine-Containing Heterocyclic Compounds Useful as Modulators of IL-12, IL-23 and/or IFNα Responses - Patent application
CN110384801B (en) 2018-04-20 2021-09-14 中国科学院上海药物研究所 Application of miRNA552 cluster microRNA in treatment of LDLC related metabolic diseases
EP3784669B1 (en) 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
US20190374526A1 (en) 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Substituted Heterocyclic Compounds as Inhibitors of PRDM9
US11442072B2 (en) 2018-07-10 2022-09-13 Jenny and Antti Wihuri Foundation Method for measuring LDL aggregation
JP7161605B2 (en) 2018-08-31 2022-10-26 ファイザー・インク Combinations for the treatment of NASH/NAFLD and related disorders
JP2022504287A (en) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー Antibodies specific for human and cynomolgus monkey APOC3, and methods of their use
RS66346B1 (en) 2018-10-22 2025-01-31 Alumis Inc Tyk2 inhibitors and uses thereof
JP2022512911A (en) 2018-11-09 2022-02-07 ノバルティス アーゲー Methods of reducing the risk of cardiovascular events using conjugated antisense compounds that target apo (a)
WO2020115288A1 (en) 2018-12-06 2020-06-11 Zora Biosciences Oy Biomarkers for cardiovascular events
BR112021013924A2 (en) 2019-01-18 2021-09-21 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USING THEM
WO2020150473A2 (en) * 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN111484480B (en) 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 Polycyclic derivative inhibitor, preparation method and application thereof
CA3128368A1 (en) 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
AU2020260110A1 (en) 2019-04-17 2021-11-11 Ngm Biopharmaceuticals, Inc. Combination therapy for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP2023506732A (en) 2019-12-10 2023-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Use of PCSK9 inhibitors to treat homozygous familial hypercholesterolemia
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
CN113713107B (en) 2020-05-26 2022-09-23 中国科学院上海药物研究所 Application of miRNA552 cluster microRNA in treatment of glycolipid metabolic disease
WO2021243002A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
MX2022015517A (en) 2020-06-10 2023-01-16 Ferring Bv PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATEROSCLEROTIC CARDIOVASCULAR DISEASE.
US20240002354A1 (en) 2020-08-05 2024-01-04 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
JP7824930B2 (en) 2020-08-19 2026-03-05 バイオジェン・エムエイ・インコーポレイテッド Treatment of hypercholesterolemia
BR112023004716A2 (en) 2020-09-15 2023-05-09 Regeneron Pharma USE OF LEPR AGONISTS FOR PAIN
US20240158382A1 (en) 2020-10-20 2024-05-16 Gbiotech S. A. R. L. Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor
KR20230104200A (en) 2020-11-05 2023-07-07 암젠 인크 Methods of treating atherosclerotic cardiovascular disease using LPA-targeted RNAi constructs
IL303130A (en) 2020-12-11 2023-07-01 Helsingin Yliopisto Method for determining a likelihood of a subject to respond to lipid lowering therapy
EP4011877A3 (en) 2020-12-11 2023-01-11 Institut de Cardiologie de Montréal Method of treating elevated plasma cholesterol
JP2024512255A (en) 2021-02-22 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods for diagnosing and treating partial lipoatrophy
US20250281495A1 (en) 2021-02-25 2025-09-11 Icahn School Of Medicine At Mount Sinai Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
AU2022248850A1 (en) 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
US12612626B2 (en) 2021-06-24 2026-04-28 Sirnaomics, Inc. siRNA compound that inhibits expression of APOC3
MX2023015442A (en) 2021-06-25 2024-03-12 Amgen Inc Treatment of cardiovascular disease with trem-1 antigen binding proteins.
WO2023285583A1 (en) 2021-07-14 2023-01-19 Eternygen Uk Ltd. 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation
WO2023052783A1 (en) 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
TW202325288A (en) 2021-11-05 2023-07-01 英商喜翠克斯治療有限公司 Novel compounds
EP4446307A4 (en) 2021-11-12 2025-12-10 Shenzhen Jingtai Tech Co Ltd Derivative of asparagic acid and its use in the treatment of metabolic disorders such as liver fibrosis and non-alcoholic hepatitis
CN114277032A (en) 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 Low-density lipoprotein receptor gene mutant and application thereof
KR20240134933A (en) 2022-01-14 2024-09-10 레주바이오 파마슈티칼스 컴퍼니 리미티드 Antidiabetic compounds and compositions
TW202345865A (en) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 Composition and method for inhibiting expression of protein LPA(Apo(a))
CN116617390A (en) 2022-02-11 2023-08-22 武汉大学 Application of ASGR1 inhibitors in promoting cholesterol efflux and treating nonalcoholic fatty liver disease
WO2023173004A2 (en) 2022-03-11 2023-09-14 University Of Florida Research Foundation, Incorporated Targeting ptchd1 and neuronal cholesterol to enhance safety of opioid analgesics
US20230338419A1 (en) 2022-03-21 2023-10-26 The Trustees Of The University Of Pennsylvania Methods and apparatus for diagnosis and detection of cardiac allograft vasculopathy
CN116948030B (en) 2022-04-25 2024-11-19 武汉大学 Anti-ASGR1 monoclonal antibody and its application
CN117045715B (en) 2022-05-13 2025-06-06 浙江养生堂天然药物研究所有限公司 Red apple and cherry plum composition and its application in anti-atherosclerosis
CN115581694A (en) 2022-11-10 2023-01-10 正大青春宝药业有限公司 Application of senkyunolide I in preparation of medicine for treating hyperlipidemia
CN117180404A (en) 2023-10-24 2023-12-08 清华大学 The use of cholesin in regulating cholesterol homeostasis
CN117482076A (en) 2023-11-24 2024-02-02 中国人民解放军陆军军医大学第二附属医院 Application of methionine compounds in the preparation of PCSK9 inhibitors

Also Published As

Publication number Publication date
CA3125767A1 (en) 2020-07-23
MA54758A (en) 2022-04-27
US20230407285A1 (en) 2023-12-21
EP3911640A4 (en) 2022-10-26
JP2025106240A (en) 2025-07-15
BR112021013924A2 (en) 2021-09-21
SG11202107615TA (en) 2021-08-30
AU2020209216A1 (en) 2021-08-26
CN113412258A (en) 2021-09-17
WO2020150474A1 (en) 2020-07-23
US20200231584A1 (en) 2020-07-23
JP2022518016A (en) 2022-03-11
US12584120B2 (en) 2026-03-24
KR20260035207A (en) 2026-03-12
MX2021008661A (en) 2021-08-19
US11603523B2 (en) 2023-03-14
EP3911640B1 (en) 2026-05-13
AU2023201972A1 (en) 2023-05-04
EP3911640A1 (en) 2021-11-24
TW202042817A (en) 2020-12-01
AU2023201972C1 (en) 2025-10-23
TWI921300B (en) 2026-04-11
IL284661A (en) 2021-08-31
EP4790054A2 (en) 2026-08-12
AU2023201972B2 (en) 2025-02-13
AU2025202886A1 (en) 2025-05-15
KR20210116549A (en) 2021-09-27
MX2024009001A (en) 2024-07-31
EA202191890A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2024009001A (en) Pcsk9 inhibitors and methods of use thereof.
PH12022551503A1 (en) Kras mutant protein inhibitors
IL284640A (en) PCSK9 inhibitors and methods of using them
IL286373A (en) Protein tyrosine phosphatase inhibitor compounds and uses thereof
DK3966207T3 (en) PHENYLAMINOPYRIMIDINAMIDE AUTOPHAGY INHIBITORS AND METHODS OF USING THEREOF
DK3966206T3 (en) HETEROARYLAMINOPYRIMIDINAMIDE AUTOPHAGY INHIBITORS AND METHODS OF USING THEREOF
MX2018013983A (en) KRAS G12C INHIBITORS.
IL308476A (en) Inhibitors of the menin-mll interaction
MA38828A1 (en) Antibodies to plasminogen activator inhibitor type 1 (pai-1) and their uses
ZA202109737B (en) Compound used as kinase inhibitor and application thereof
IL281451A (en) Uses of Plasminogen Activator Inhibitor 1 (PAI-1) Inhibitors
ZA202202245B (en) Quinoline derivatives as protein kinase inhibitors
IL291158A (en) Iraq inhibitor and the method of preparation therefor and its use
IL281450A (en) Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses thereof
EP4240363A4 (en) 7-PHENYL-SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1
EP4333821A4 (en) INHIBITORS OF SARS-COV-2
EA201790484A1 (en) Derivatives of tetrahydroquinoline as bromodomain inhibitors
EA202192575A1 (en) DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT
EA201892051A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MALIGNANT NON-FORMATION
EP4240361A4 (en) 7-AZOLE-SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1
JOP20230205A1 (en) Vmat2 inhibitors and methods of use
EP4384164A4 (en) INHIBITORS OF HYPOXI-INDUCIBLE FACTORS
EP4069229A4 (en) SOLID STATE FORMS OF HDAC INHIBITOR
EA201992200A1 (en) MICROINCapsULATED NITRIFICATION INHIBITOR COMPOSITIONS
IL291368A (en) Inhibitor of metadherin expression